RefleXion Medical is highlighting eight clinical abstracts at the upcoming American Society for Radiation Oncology (ASTRO) 2022 annual meeting in San Antonio, TX.
The abstracts will evaluate the potential use and utility of the company's treatment planning for prostate cancer radiotherapy, its ring gantry-based PET/CT linear accelerator, and its technology for metastatic non-small cell lung cancer.
The company also plans to introduce a new product name for its BgRT technology and treatment offering, which will now be called Scintix.
